Introduction: Who Should Undergo Diagnostics and When
If you notice something unusual in your mouth, throat, or neck area that doesn’t go away within a few weeks, it’s time to see a doctor. Squamous cell carcinoma of the head and neck, often called HNSCC, develops in the squamous cells that line the moist surfaces inside your mouth, nose, and throat. These are thin, flat cells that make up the outer layer of these tissues, and when they become cancerous, they can cause symptoms that are easy to overlook at first.[1][2]
A persistent sore throat that lasts more than two weeks is the most common warning sign that something might be wrong. Many people assume it’s just a cold or infection that will clear up on its own, but when throat pain lingers without improvement, it deserves medical attention. Other symptoms that should prompt you to seek diagnostic evaluation include a lump in your neck, mouth sores that won’t heal, difficulty swallowing, ear pain that doesn’t match with an ear infection, or voice changes that persist. These symptoms can feel vague and minor at first, which is why many people delay seeking care.[5][14]
People with certain risk factors should be especially vigilant about seeking diagnostics when symptoms appear. If you use tobacco products, including cigarettes or chewing tobacco, or if you consume alcohol heavily, your risk of developing HNSCC is significantly higher. Tobacco and alcohol are the two strongest risk factors for this type of cancer, especially when used together. Infection with certain strains of human papillomavirus, or HPV, particularly HPV-16, has also emerged as an important risk factor, especially for cancers in the middle part of the throat near the tonsils and base of the tongue.[2][3]
Importantly, HNSCC has been increasing among younger individuals, often related to HPV infection. This shift means that even people in their 30s and 40s should take persistent head and neck symptoms seriously, not just older adults with a history of tobacco use. The earlier the disease is caught, the better the chances of successful treatment and the less intensive the treatment may need to be.[6][14]
Diagnostic Methods for Identifying the Disease
When you visit a healthcare provider with symptoms that might suggest head and neck cancer, the diagnostic process typically begins with a thorough examination of your head and neck area. This physical examination is straightforward but essential. Your doctor will look inside your mouth using a light and mirror to check for sores, unusual patches, or other abnormalities. They will also carefully feel your neck for lumps or swelling, especially in the areas where lymph nodes are located. Enlarged lymph nodes in the neck can be a sign that cancer has spread from its original location.[13][21]
For areas that are harder to see, such as the back of the throat, the nasal passages, or the voice box, doctors use specialized tools. A tiny camera attached to a flexible tube can be gently inserted through your nose or mouth to examine these hidden areas. This procedure, called endoscopy, allows the doctor to see the tissues in detail and look for signs of cancer. It may feel uncomfortable, but it’s usually not painful, and it provides crucial information about what’s happening inside your head and neck.[13][21]
Imaging tests play a vital role in diagnosing HNSCC and determining how far it has spread. These tests create detailed pictures of the inside of your body without surgery. A CT scan, or computed tomography scan, uses X-rays taken from different angles to create cross-sectional images of your head and neck. This helps doctors see the size and location of a tumor and whether it has affected nearby structures like bones or blood vessels. An MRI scan, or magnetic resonance imaging, uses powerful magnets and radio waves instead of X-rays to create detailed images of soft tissues. MRI is particularly good at showing the extent of tumors in soft tissue areas.[13][21]
A PET scan, or positron emission tomography scan, is another imaging test that may be used. This test involves injecting a small amount of radioactive sugar into your bloodstream. Cancer cells, which grow rapidly and use more energy than normal cells, absorb more of this sugar and show up as bright spots on the scan. PET scans are especially useful for detecting whether cancer has spread to other parts of the body, such as the lungs or distant lymph nodes.[13][21]
The most definitive diagnostic test for HNSCC is a biopsy, which involves removing a small sample of tissue from the suspicious area so it can be examined under a microscope. How the biopsy is performed depends on where the suspected cancer is located. If the abnormal area is easy to reach, such as inside the mouth, the doctor can cut out a small piece of tissue using special instruments. For areas that are harder to access, a needle may be inserted through the skin and into the tumor to draw out some cells. In some cases, special tools used during an endoscopy can collect tissue samples from inside the throat or nose.[13][21]
The tissue sample collected during a biopsy is sent to a laboratory where specialists called pathologists examine it. They look at the cells under a microscope to determine if they are cancerous. If cancer is present, the pathologist can identify what type of cancer it is and how abnormal the cells appear. This information is crucial for planning treatment. Additional specialized tests on the biopsy sample can reveal important details about the cancer’s characteristics, including whether it’s related to HPV infection. HPV-positive and HPV-negative HNSCC are now recognized as distinct types of disease with different prognoses and treatment approaches.[4][6]
Sometimes, cancer cells are found in lymph nodes in the neck, but doctors cannot initially find where the cancer started. When this happens, the cancer is called metastatic squamous cell carcinoma with unknown primary. In such cases, doctors conduct extensive examinations of the entire head and neck region to try to locate the original tumor. Even if the primary tumor cannot be found, the presence of squamous cell cancer in neck lymph nodes is treated as HNSCC because the cancer almost always originates somewhere in the head and neck area.[2][10]
Diagnostics for Clinical Trial Qualification
If you’re considering participating in a clinical trial for head and neck squamous cell carcinoma, you’ll need to undergo additional diagnostic tests beyond those used for standard diagnosis. Clinical trials are research studies that test new treatments or new ways of using existing treatments. To ensure the safety of participants and the reliability of study results, clinical trials have strict criteria, called eligibility criteria, that determine who can participate.
One of the most important eligibility factors is the stage of your cancer, which describes how large the tumor is and how far it has spread. The traditional tumor-node-metastasis system, or TNM system, is used to assign a stage to your cancer. The “T” describes the size and extent of the main tumor, the “N” describes whether cancer has spread to nearby lymph nodes, and the “M” indicates whether cancer has spread to distant parts of the body. This staging information comes from the physical examination, imaging tests, and biopsy results you’ve already had. In 2017, an updated staging system was introduced that includes additional information specifically for HPV-positive disease, because these cancers behave differently from HPV-negative cancers.[4][6]
Clinical trials often require confirmation of your cancer’s molecular characteristics. For HNSCC, one of the most important tests is determining whether your tumor is HPV-positive or HPV-negative. This is typically done by testing the biopsy tissue for the presence of HPV DNA or proteins. HPV status can significantly affect which clinical trials you’re eligible for, because many newer trials are designed specifically for one group or the other. HPV-positive HNSCC generally has a better prognosis than HPV-negative disease, and researchers are working to develop treatments tailored to each type.[4][6]
Some clinical trials focus on targeted therapies, which are treatments designed to attack specific genetic changes or proteins found in cancer cells. To participate in these trials, you may need additional molecular testing of your tumor tissue. For example, tests might look for mutations in genes like TP53, NOTCH1, or CDKN2A, or for abnormalities in proteins like EGFR, which stands for epidermal growth factor receptor. These tests help determine whether your cancer has the specific characteristics the treatment is designed to target.[3][6]
Blood tests are also commonly required for clinical trial participation. These tests assess your overall health and organ function to ensure that you can safely tolerate the experimental treatment. Standard blood tests might include a complete blood count to check your levels of red blood cells, white blood cells, and platelets, as well as tests to evaluate your kidney and liver function. These are important because many cancer treatments can affect these organs.[9]
For trials testing immunotherapy treatments, which harness your immune system to fight cancer, additional diagnostic tests may examine immune markers in your tumor. These might include tests to measure the levels of proteins like PD-L1 (programmed death-ligand 1) on the surface of cancer cells or immune cells within the tumor. Higher levels of PD-L1 may predict better responses to certain immunotherapy drugs. Several immunotherapy drugs, including pembrolizumab and nivolumab, have been approved for HNSCC, and many clinical trials are exploring new immunotherapy approaches.[6][9][11]
Performance status is another important criterion for clinical trial eligibility. This is a measure of how well you can carry out normal daily activities and is typically assessed by your doctor during a physical examination. Trials often require that participants be well enough to care for themselves and be active for at least half of their waking hours. This ensures that participants can tolerate the treatment being studied.
